Accès ouvert

Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19: Study on paired series

Article scientifique 2022 Anglais

Résumé

Abstract We designed a comparative study on two paired series of critical patients affected with Covid-19: the 1st group received Tocilizumab (TCZ) plus standard care (SC) versus a 2nd group which received only SC. Outcomes were: survival, mechanical ventilation (MV) and nosocomial infections. Ninety patients were included by pairing (n=45 in each group). 55.5% of SC group progressed to stage 3-acute respiratory distress syndrome (ARDS) versus 31% of TCZ+SC patients (p=0.03). No effect of TCZ was found on mortality (49% in each group, p=1) nor on MV use (p=0.67). ICU stay was more prolonged in TCZ+SC group (16 versus 8 days, p <10-3). The administration of TCZ induced a significant decrease in CRP but not changed the IL-6 dosage. Nosocomial infections occurred in 18 (40%) of TCZ+SC group comparatively to 15 (33,5%) of SC group, p=0.66. We concluded to no real clinical impact benefit of TCZ in this kind of patients.

Citer ce document

Trifi, A., Abdennebi, C., Romdhane, K., Blel, Y., Daly, F., Zakhama, B., Mestiri, T., Abdellatif, S., Lakhal, S. (2022). Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19: Study on paired series. https://doi.org/10.21203/rs.3.rs-1374927/v1

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Ahlem Trifi Cyrine Abdennebi Kaïs Ben Romdhane Youssef Blel Foued Daly B Zakhama Taher Mestiri Sami Abdellatif Salah Ben Lakhal

Statistiques

Consultations : 1

Téléchargements : 0